PTPN11 and neoplasm: CDK4/6 inhibitor increased the efficacy of SHP2 inhibitor TNO155 by enhancing RB activity, greater inhibited cell cycle and apoptosis inhibitory proteins, which resulted in deeper and more sustained anti-tumor activity in malignant peripheral nerve sheath tumor models38.